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Edited by Gianni CesareniAbstract The mechanisms regulating expression of breast can-
cer 1 (BRCA1) are not fully characterised. By studying regula-
tion of endogenous BRCA1 in human epithelial cell lines and
during cell cycle progression, we provide evidence to suggest
BRCA1 is regulated post-transcriptionally at the level of messen-
ger RNA stability. We also show that RNA-binding proteins
associate with an AU-rich, cis-active sequence of the BRCA1
3 0untranslated region in a cell cycle-dependent manner. Our data
identify a new post-transcriptional regulatory axis and a novel
mechanism for modulating the levels of BRCA1 protein, with
possible implications for understanding the mechanisms underly-
ing BRCA1 repression in breast cancer.
 2007 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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Breast cancer 1 (BRCA1) is a large, nuclear phosphoprotein
with multiple functions, including maintaining genome stabil-
ity, regulating mitotic spindle formation, and regulating the
cell cycle (reviewed in [1]). It has been suggested that dysregu-
lation of BRCA1 expression occurs in sporadic breast cancer,
with reduced messenger RNA (mRNA) and/or protein levels
a feature in the majority of cases [2,3]. Accordingly, there is
considerable interest in the mechanisms that control normal
and abnormal regulation of BRCA1.
Post-transcriptional regulation of gene expression has
evolved as a means of ﬁne-tuning protein levels and generating
rapid temporal or spatial changes in protein expression follow-
ing an environmental stimulus (reviewed in [4]). Regulation of
the dynamics of mRNA molecules is a widespread phenome-
non, and there are many examples of genes regulated in this
way, including tumour suppressor genes [5–7]. The mecha-
nisms often involve RNA-binding proteins and non-codingAbbreviations: 3 0UTR, 3 0untranslated region; BRCA1, Breast Cancer
1; FACS, ﬂuorescence-activated cell sorting; hnRNA, heterogeneous
nuclear RNA; HO342, hoechst 33342; mRNA, messenger RNA;
REMSA, RNA-electrophoretic mobility shift assay; RNA-BP, RNA-
binding protein; RPC, RNA–protein complex; UVX, ultraviolet cross-
linking
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doi:10.1016/j.febslet.2007.06.046RNAs (trans-acting factors), which recognise sequence motifs
in their target transcripts and ‘‘tag’’ them for recognition by
macromolecular complexes involved in RNA metabolism,
such as mRNA transport granules, RNA-induced silencing
complexes (RISC), the exosome, GW bodies and stress gran-
ules (reviewed in [8–11]). There are many examples of post-
transcriptional regulatory motifs, including CU-rich, U-rich
and AU-rich elements, which are usually located in the 5 0
and 3 0untranslated regions of regulated transcripts (e.g. [12–
14]). It can be diﬃcult to predict the regulatory functions of
individual motifs based on primary sequence alone, as they of-
ten associate with multiple trans-acting factors with diﬀerent
and sometimes opposing activities. It is thought that the regu-
latory fate of each transcript is determined by the precise bal-
ance of such factors associated with the transcript at any one
time (reviewed in [9]). Post-transcriptional dysregulation has
been associated with the aetiologies of several human diseases,
including breast cancer [15–18]. Two studies have addressed
regulation of BRCA1 translation eﬃciency by its 5 0 UTR
[19,20], however in general, post-transcriptional regulation of
BRCA1 is poorly characterised.
BRCA1 expression is regulated in several cellular processes,
including the cell cycle. Experiments conducted in the mid to
late 1990s reported that BRCA1 mRNA levels peak late in
G1 phase and early S phase [21–23], and protein level is max-
imal in S phase and remains elevated until M phase [21,24].
This cell cycle-dependent expression pattern is thought to facil-
itate the functions of BRCA1 in maintaining genomic stability
and regulating cell cycle checkpoints [25,26]. Although one
group has shown that changes in the levels of proteasome-sen-
sitive BRCA1-ubiquitin conjugates are involved [27], the regu-
latory mechanisms underlying the principle changes in mRNA
expression throughout the cell cycle have not been investi-
gated. The fact that post-transcriptional regulation of other
genes, such as Cyclin A and p27Kip1, contributes to their cell
cycle-dependent expression [5,28] raises the possibility that
BRCA1 may be regulated by similar mechanisms. This study
addresses the hypothesis that BRCA1 is regulated post-trans-
criptionally, speciﬁcally at the level of mRNA stability.2. Materials and methods
2.1. Cell culture
HeLa (ATCC#CCL-2), MDA-MB-468 (ATCC#HTB-132), T-47D
(ATCC#HTB-133), MCF7 (ATCC#HTB-22; provided by Mike
Waters, UQ) and SVCT (ECACC#94122105) cells were cultured
according to the manufacturer’s recommendations, and MCF10a cells
(ATCC#CRL-10317) as previously described [29].blished by Elsevier B.V. All rights reserved.
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Protein extracts were prepared using RIPA lysis buﬀer, and BRCA1
protein levels were analysed relative to b-actin by Western analysis as
described [3,30], on tris-acetate 3–8% polyacrylamide gradient gels
(Invitrogen). For analysis of protein integrity, extracts were resolved
by SDS–PAGE, and silver-stained according to the Amersham Phar-
macia Biotech PlusOne silver staining protocol for mini-gels.
2.3. Real-time RT-PCR
Total RNA was isolated using TRIZOL (Invitrogen), and DNAse-
treated using DNA-free (Ambion). cDNA was synthesised using
PowerScript (Clontech), with the following primers: BRCA1RT (5 0-
CTGGATTTCGCAGGTCCT-3 0), 18SrRNART (5 0-AGA-
GGCAAGGGGCGGGGA-3 0). 18S rRNA was chosen as the internal
standard as it shows little variation in expression throughout the cell
cycle [31]. BRCA1 hnRNA, BRCA1 mRNA and 18S rRNA were
quantiﬁed on an ABI Prism 7000 Sequence Detection System with
ABI Prism 7000 SDS software (v1.0; Applied Biosystems). Reactions
contained SYBR green PCR master mix (Applied Biosystems), prim-
ers (BRCA1 mRNA, 200 nM; BRCA1 hnRNA and 18S rRNA,
50 nM) and template diluted appropriately in dH2O. Cycling condi-
tions were: 10 min (95 C), followed by 45 cycles of 15 s (95 C), and
1 min (58 C). PCR primers used were: BRCA1 mRNA, exon12_F
(CTGCTCAGGGCTATCCTCTCA-3 0) and exon13_R (5 0-
GCTTCTAGTTCAGCCATTTCCTG-3 0); BRCA1 hnRNA, in-
tron12_F (5 0-AGTATTTCATTTTCTTGGTGCCATT-30) and
exon13_R; 18S rRNA, 18S_F (5 0-CATTGGAGGGCAAGTCTGG-
3 0) and 18S_R (5 0-TCCCAAGATCCAACTACGAGC-30) (Fig. 2B).
No reverse-transcriptase controls were conducted for genomic DNA
contamination. PCR products were sequenced by the Australian Gen-
ome Research Facility (data not shown). The comparative DCt method
(Applied Biosystems) was used to determine relative BRCA1 mRNA
and hnRNA expression, taking into account the primer set eﬃciencies
(E values): target/18S = (E18S)
Ct18S/(Etarget)
Ct target [32]. Mean E values
calculated from two independent experiments were: BRCA1 hnRNA,
1.9544; BRCA1 mRNA, 1.7364, 18S rRNA, 1.9998.
2.4. mRNA stability assays
BRCA1 and luciferase mRNAs were quantiﬁed relative to 18S rRNA
or Renilla luciferase mRNA, respectively, at various times after addi-
tion of Actinomycin D (ActD; 6.5 lg/mL; Sigma–Aldrich) to the cell
culture medium. RNA was extracted from treated cells using TRIZOL
(Invitrogen), and RNA species were detected by Northern analysis and
phosphorimaging using standard procedures, or real-time RT-PCR as
described above. RNA half-life (t1/2) was calculated by linear regression
analysis, and for cell cycle experiments one-way analysis of variance
(ANOVA) was conducted to test the signiﬁcance of diﬀerences between
BRCA1 mRNA decay slopes (GraphPad Prism software; v3.0).
2.5. Fluorescence-activated cell sorting (FACS)
HeLa cells were stained for 20 min in a 37 C shaking water bath
with 4 lg/mL hoechst 33342 (HO342; Sigma–Aldrich) in fresh media
at 1 · 106 cells/mL. Cells were resuspended in Cell-free Dissociation
Buﬀer (Invitrogen), ﬁltered and chilled to minimise HO342 leakage.
Sorting into cell cycle subpopulations was done by MoFlo (Cytoma-
tion) FACS with Summit software (v3.1; Cytomation). For ActD
experiments, HO342 ﬂuorescence boundaries were determined for un-
treated cells, then extrapolated to treated populations. G1 doublets
(possible 4N false positives), cells with >4N DNA content, cell debris
and apoptotic cells were ﬁltered out.2.6. Luciferase reporter assays
Dinucleotide substitutions (UU > GG) were introduced into a pSG5
(Stratagene)-based reporter construct containing the BRCA1 3 0UTR
sequence downstream of the luciferase coding sequence, using a Quik-
Change mutagenesis kit (Stratagene). Transient transfections into
HeLa cells and luciferase reporter assays were performed as previously
described [33].2.7. RNA–protein binding assays
Radiolabelled RNA probes containing BRCA1 3 0UTR nts 235–351
were prepared using the T7 Riboprobe in vitro transcription kit (Pro-
mega) in the presence of [a-32]P-UTP (Perkin–Elmer). RIPA proteinextracts were prepared as above. Analysis of RNA–protein interac-
tions was performed by RNA-electrophoretic mobility shift assay (RE-
MSA) essentially as described [34]. For ultraviolet cross-linking (UVX)
experiments, RNA–protein mixtures were processed identically to RE-
MSA reactions, then treated with 3 · 105 lJ UVC radiation (254 nm)
for 5 min on ice. Unlinked RNA was degraded with RNAse A (Sig-
ma–Aldrich; 100 lg/mL) for 10 min at 37 C. Proteins were resolved
by SDS–PAGE, then imaged by phosphorimaging.3. Results
3.1. Lack of association between BRCA1 protein levels, mRNA
levels and mRNA stability in human epithelial cell lines
If regulation of BRCA1 expression was predominantly tran-
scriptional, a strong correlation between mRNA and protein
levels would be expected. In contrast, a poor correlation
may suggest post-transcriptional mechanisms are important
determinants of protein levels. To investigate this, BRCA1
mRNA and protein levels, and mRNA stability were deter-
mined across a panel of six human epithelial cell lines, using
Western analysis (Fig. 1A), real-time RT-PCR (Fig. 1B) and
actinomycin D (ActD) mRNA stability assays (Fig. 1C),
respectively. There was variability in the mRNA–protein cor-
relation observed, with mRNA expression level being an indi-
cator of protein levels in some cell lines (HeLa, MDA-MB-
468 and MCF10a), but not in others (T-47D, SVCT and
MCF7) (Fig. 1D). mRNA stability was predictive of protein
levels in T-47D cells, but not the other cell lines, including
those in which mRNA levels were also not predictive of pro-
tein expression (SVCT and MCF7). Overall, the lack of asso-
ciation between BRCA1 mRNA levels and stability with
protein levels suggests that post-transcriptional mechanisms
likely contribute to the ﬁnal amount of BRCA1 protein ex-
pressed, including regulation of mRNA stability and possibly
other mechanisms, such as mRNA translation eﬃciency or
protein stability.
3.2. BRCA1 is regulated transcriptionally and post-
transcriptionally during cell cycle progression
In order to study regulation of BRCA1 expression during
cell cycle progression, HeLa cells were physically segregated
into four populations by FACS according to DNA content
(H1-4). After sorting, the four groups were re-analysed by ﬂow
cytometry to conﬁrm the relative proportions of cells in diﬀer-
ent phases of the cell cycle. As shown in Fig. 2A, populations
H1-4 contained decreasing proportions of cells in G1 phase,
and increasing proportions of cells in G2/M phase. These four
populations of sorted cells were used for BRCA1 expression
analysis.
To investigate the relative contributions of transcriptional
and post-transcriptional mechanisms to regulation of BRCA1
during cell cycle progression, a real-time RT-PCR strategy
was used, with primer sets that distinguish between nascent
BRCA1 transcripts (hnRNA) and mature BRCA1 mRNA
(Fig. 2B) [35]. This analysis showed there was a progressive in-
crease in BRCA1 mRNA levels from H1 to H3 (Fig. 2C), rep-
resenting cells with decreasing proportions of cells in G1 phase
relative to cells in S and G2/M phases (Fig. 2B). Interestingly,
this was not paralleled by an increase in BRCA1 hnRNA in
H1-3, suggesting that transcriptional mechanisms do not sig-
niﬁcantly contribute to the changes in mRNA levels observed.
Fig. 2C also shows there were decreases in both BRCA1
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Fig. 1. Poor correlation between BRCA1 protein levels, mRNA levels and mRNA stability in human epithelial cell lines. (A) Representative Western
analysis of BRCA1 protein expression in six human epithelial cell lines using equal amounts of total protein extract. b-Actin was analysed as a
protein loading control. (B) Representative real-time RT-PCR analysis of BRCA1 mRNA expression in the same six cell lines. BRCA1 mRNA
expression was determined using primers that span an intron too large to be ampliﬁed in the PCR, and normalised to 18S rRNA. Data shown are
means ± S.E. of the mean for three replicates (representative of two biological replicates). (C) Analysis of BRCA1 mRNA stability in human
epithelial cell lines. Cells were treated with the transcription inhibitor actinomycin D (Act D), and total RNA was harvested at 0, 3, 6 and 9 h post-
treatment. BRCA1 mRNA levels were determined relative to 18S rRNA by Northern analysis, and quantitated by phosphorimaging. Normalised
BRCA1mRNA level (BRCA1:18S) is shown as a function of ActD treatment time to illustrate decay kinetics. BRCA1mRNA half-life (t1/2), the time
taken for half the number of original molecules to decay, was determined by linear regression analysis. (D) Comparison of BRCA1 protein levels,
mRNA levels and mRNA stability in the panel of cell lines – each parameter for each cell line was classiﬁed as high (***), medium (**) or low (*)
relative to the other cell lines for comparison.
J.M. Saunus et al. / FEBS Letters 581 (2007) 3435–3442 3437mRNA and hnRNA levels in H4, which contained a high pro-
portion of cells in G2/M phase relative to cells in S and G1
phases (Fig. 2B), suggesting cells in G2 phase may have a lower
rate of BRCA1 transcription and correspondingly lower levels
of BRCA1 mRNA.
To investigate the contribution of changes in BRCA1
mRNA stability to its cell cycle expression pattern, mRNA de-
cay rate was analysed in FACS-sorted HeLa populations.
Asynchronous HeLa cells were treated with ActD, then
FACS-sorted at 0, 2, 4.75 and 7 h after ActD treatment. The
experimental timeframe was limited to 7 h (cf. cell line experi-
ments; Fig. 1) to maximise conﬁdence that cell cycle history
would be largely reﬂected in the stage of cells at sorting.
BRCA1 mRNA levels were measured by real-time RT-PCR
as described above, for each population, at each time-point
(Fig. 2D). This analysis showed BRCA1 mRNA was very sta-ble (t1/2  20 h) in H1-2, which contained the highest propor-
tions of cells in G1 phase, but was less stable (t1/2  7 h) in
H3-4, which contained increasing proportions of G2/M phase
cells. The diﬀerence between H1-2 and H3-4 was statistically
signiﬁcant (P < 0.0001). This suggests that changes in BRCA1
mRNA stability are likely to contribute to regulation of
BRCA1 expression throughout the cell cycle.
3.3. An AU-rich subsequence of the BRCA1 3 0UTR can regulate
luciferase mRNA stability and associates with RNA-binding
proteins in a cell cycle-dependent manner
Regulation of mRNA stability is often mediated by RNA-
binding proteins (RNA-BPs) that bind to 3 0UTR regulatory
motifs, such as AU-rich sequences (reviewed in [36]). Primary
sequence analysis of the BRCA1 3 0UTR revealed an AU-rich
sequence at nts 292–300 (Fig. 3A). In order to investigate
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Fig. 2. Changes in BRCA1 expression during cell cycle progression are associated with changes in BRCA1 transcription and mRNA stability. (A)
Representative cell cycle distributions in FACS-sorted HeLa cells. Asynchronous HeLa cells were stained with hoechst 33342 and analysed by ﬂow
cytometry. Stained cells were sorted into four populations by FACS based on ﬂuorescence (H1-4), proportional to DNA content. Debris, dead cells
and cell doublets were ﬁltered out. Sorted cells were re-analysed by ﬂow cytometry to determine proportions of cells in G1, S and G2/M phases,
compared to the original source population (HeLa). (B) Schematic showing BRCA1- and 18S rRNA-speciﬁc primers. Gene-speciﬁc reverse
transcription primers were used to amplify 18S rRNA, BRCA1 hnRNA and BRCA1mRNA from each sample. Primer pairs that distinguish between
BRCA1 hnRNA and mRNA were used in subsequent real-time PCRs. 18S rRNA was ampliﬁed in parallel reactions as a loading control. (C)
Analysis of BRCA1 hnRNA (crosses) and mRNA (circles) expression in FACS-sorted HeLa cells by real-time RT-PCR, using the strategy in (B).
Data shown are means from at least six measurements (including three independent FACS experiments) ± the standard error of the mean (S.E.M.).
(D) Changes in BRCA1 mRNA stability during cell cycle progression. BRCA1 mRNA levels from sorted HeLa cells (H1-4) were determined over a
time-course after treatment with actinomycin D. Levels of BRCA1 mRNA remaining after treatment were calculated as percentages of the levels at
time zero (0 h). BRCA1 mRNA half-life (t1/2) is shown. Data shown are means ± S.E.M. of three PCR replicates; representative of two biological
replicates.
3438 J.M. Saunus et al. / FEBS Letters 581 (2007) 3435–3442whether this sequence could be involved in regulating mRNA
stability, we examined the eﬀects of mutagenising this sequence
on the regulatory activity of the full-length BRCA1 3 0UTR.
Based on methodologies utilised by others for investigating
the functions of AU-rich sequences (e.g. [37,38]), a UU > GG
double base-pair substitution was introduced into a luciferase-
BRCA1 3 0UTR reporter construct by site-directed mutagenesis(296UU > GG; Fig. 3A), then transfected into HeLa cells. As
shown in Fig. 3B, the mutant sequence conferred negative reg-
ulatory activity on the BRCA1 3 0UTR compared to the wild-
type (WT) sequence. Actinomycin D experiments suggested
this was at least partly attributable to a decrease in mRNA sta-
bility, with mRNA half-life decreasing from 12 to 9 h
(Fig. 3C).
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Fig. 3. Mutation of a BRCA1 3 0UTR AU-rich sequence confers
reduced luciferase reporter activity and mRNA stability. (A) Sche-
matic showing luciferase constructs used to analyse the activity of
theBRCA1 3 0UTR. (B) HeLa cells were transiently transfected with
luciferase constructs containing either the full-length, wild-type (WT)
BRCA1 3 0UTR sequence, or a mutated version (UU > GG dinucleo-
tide substitution at nt296). Luciferase activity was determined relative
to a cotransfected Renilla luciferase control and graphed as a
percentage of WT. Data shown are means ± S.D.s from three
replicates. (C) HeLa cells were transfected with luciferase reporter
constructs as in (B), and luciferase mRNA was quantiﬁed relative to
Renilla RNA at 0, 3, 6 and 9 h after treatment with actinomycin D.
Luciferase mRNA half-life (t1/2) was determined using linear regression
analysis. Data at each timepoint represent the means ± S.D. from three
replicates.
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sequence may have post-transcriptional regulatory activity,
we also tested whether the formation and/or constitution of
BRCA1 3 0UTR RNA–protein complexes (RPCs) vary during
cell cycle progression, as this may indicate a role for RNA-
BPs in cell cycle-dependent regulation of BRCA1. A radio-
labelled RNA probe containing the AU-rich sequence
(Fig. 4A) was incubated with protein extracts from FACS-
sorted HeLa cells (H1-4; Fig. 4B). As shown in Fig. 4C, the
probe formed several RPCs with proteins from H1-3 compara-
bly to each other and to the source HeLa population, but no
prominent RPCs were detected using H4 extracts. These re-sults suggest the RNA-BPs required may be absent or inactive
in the H4 extract, which contained the highest and lowest pro-
portions of cells in G2/M and G1 phases, respectively
(Fig. 2B).
To investigate the RNA-BP composition of RPCs during
cell cycle progression, UV cross-linking analysis was per-
formed. Whilst RPCs from H1-3 migrated similarly under na-
tive conditions (Fig. 4C), Fig. 4D shows that the composition
of these complexes changes; speciﬁcally RNA-BPs A, B, C and
H. For example, binding by RNA-BP A was only weakly de-
tected in the H1 extract, but more strongly detected in H2-3,
whereas RNA-BPs B, C and H were detected weakly in H2-3
compared to H1. Consistent with native gel analysis in
Fig. 4C, none of these proteins were detected in H4 extracts.
These results suggest that the individual RNA-BPs that associ-
ate with the AU-rich BRCA1 3 0UTR probe may be diﬀeren-
tially expressed and/or active during cell cycle progression.4. Discussion
A comprehensive understanding of the mechanisms regulat-
ing BRCA1 expression under normal conditions is requisite to
identifying regulatory abnormalities in cancer. There are mul-
tiple reports documenting a reduction in BRCA1 expression in
sporadic breast cancer (e.g. [2,3]), however the possibility that
disruption of post-transcriptional processes may be involved
has not been investigated; in fact the post-transcriptional
mechanisms regulating normal BRCA1 expression are poorly
understood. This study provides new results suggesting that
BRCA1 mRNA stability is regulated throughout the cell cycle,
a biological process in which BRCA1 has a critical role [25,26].
In the present study, BRCA1 mRNA half-life was found to
be highly variable between cell lines (5–35 h). Studies of other
genes regulated at the level of mRNA stability have provided a
range of reference mRNA half-lives, from labile transcripts
such as c-myc (t1/2  10 min) to extremely stable transcripts
of housekeeping genes (e.g. GAPDH; t1/2 > 24 h) (reviewed
in [36]). Thus in the present study, BRCA1 mRNA ranged
from moderately stable to extremely stable in diﬀerent cell
lines. Comparison of relative mRNA levels and stabilities be-
tween cell lines showed that neither was a consistent indicator
of protein expression, suggesting that the regulatory mecha-
nisms controlling BRCA1 expression are likely to be complex.
A poor correlation between mRNA and protein levels is com-
mon in both humans and yeast, and can signify that post-tran-
scriptional regulatory processes are the rate-limiting
determinants of protein expression [39,40].
To investigate whether post-transcriptional regulation of
BRCA1 occurs in a normal biological process, we investigated
BRCA1 expression and mRNA stability during cell cycle pro-
gression using FACS-sorted HeLa cells containing diﬀerent
proportions of cells in G1, S and G2/M phases (Fig. 2).
BRCA1 mRNA was normalised to 18S rRNA, which is very
stable, and expressed constitutively throughout the cell cycle
compared to protein-coding genes [31]. We observed an in-
crease in the levels of BRCA1 mRNA as the proportions of
cells in S and G2/M phases increased, and the G1 cell propor-
tion decreased, consistent with previous reports that BRCA1
mRNA levels increase as cells enter S phase [21–23]. Interest-
ingly, this was not associated with any change in hnRNA level
(unlike the H4 population), suggesting it may be due to post-
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Fig. 4. Dynamic association of RNA-binding proteins with a BRCA1 3 0UTR RNA probe throughout the cell cycle. (A) Schematic showing the cis-
active AU-rich sequence relative to the 3 0UTR sequence selected for RNA–protein-binding studies (235–351). (B) Silver-stained SDS–PAGE analysis
of whole cell protein extracts from FACS-sorted HeLa cells (H1-4). (C) Analysis of BRCA1 3 0UTR RNA–protein complex formation by REMSA.
No protein (no prot), or equal amounts of protein extracts from asynchronous or sorted HeLa cells (H1-4) were incubated with equal amounts of a
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resolved by native PAGE and imaged by autoradiography. Results are representative of cells FACS-sorted on two separate occasions. (D) SDS–
PAGE analysis of RNA-BPs throughout the cell cycle. RNA–protein mixtures were treated with UVC radiation to cross-link RPCs, then uprotected
RNA was degraded with RNAse A and proteins were resolved by SDS–PAGE. RNA-BPs (arrowheads) linked to radiolabelled RNA were imaged by
phosphorimaging. Results are representative of cells FACS-sorted on two separate occasions.
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ysis of BRCA1 mRNA stability in the sorted populations
showed there are clear diﬀerences during cell cycle progression,
with the high G1-content populations (H1-2) containing very
stable BRCA1 transcripts (t1/2  20 h) and high G2/M-content
populations (H3-4) containing less stable transcripts
(t1/2  7 h). A three-fold change in mRNA stability is within
the range considered to be biologically signiﬁcant for the cell
cycle-regulated transcripts encoding cyclin A and histone H3
[5,41]. This is the ﬁrst demonstration that changes in BRCA1
mRNA stability occur during cell cycle progression. The fact
that the changes in BRCA1 transcript stability during cell cycle
progression diﬀer from that of other transcripts, such as his-
tones (t1/2 decreases from G1 to S phase, reviewed in [42]),
cyclin A (t1/2 increases from G1 to G2 phase [5]), and cyclin
E (t1/2 relatively invariable throughout the cell cycle [5]), sug-
gest its regulation is speciﬁc, rather than a general consequence
of cell cycle progression.
In the present study, BRCA1 mRNA levels did not change
dramatically during cell cycle progression. Others have re-
ported that BRCA1 mRNA levels increase signiﬁcantly uponentry into S phase relative to barely detectable levels in growth
factor-deprived or lovastatin-arrested cells (G0/G1) [21–23].
One possible explanation for this discrepancy is that the cell
cycle expression pattern is cell line-dependent. Another is that
the expression pattern may diﬀer in chemically synchronised
versus physically segregated (e.g. FACS) cell cycle popula-
tions. Studies in yeast have shown signiﬁcant diﬀerences in
the cell cycle expression patterns of selected genes using these
two diﬀerent approaches [43]. It has been proposed that
changes in gene expression reported in synchronised cells
may be consequences of stress rather than cell cycle stage
[44–46]. Furthermore, some of the synchronising treatments
used in previous studies are implicated in BRCA1 regulation.
For example, lovastatin downregulates of E2F [47], a tran-
scriptional activator of BRCA1 [48]. Thus, it is possible that
cells arrested in G1 phase by lovastatin treatment express
low levels of BRCA1 mRNA because of downstream eﬀects
of the drug rather than the cellular environment in that cell cy-
cle stage. Additionally, growth factor withdrawal causes a de-
crease in BRCA1mRNA levels [23], which brings into question
the low levels of BRCA1 mRNA reported in growth factor-de-
J.M. Saunus et al. / FEBS Letters 581 (2007) 3435–3442 3441prived, G0-arrested cells, or in cells recovering from G0 arrest
(early G1 phase). These concerns suggest that analysis of non-
synchronised cells would most accurately reﬂect cell cycle reg-
ulation of BRCA1.
In this study, we attempted to identify sequence motifs that
could be involved in post-transcriptional regulation of
BRCA1, speciﬁcally mRNA stability. Mutagenesis experi-
ments, reporter assays and RNA–protein-binding analysis sug-
gest that an AU-rich sequence at BRCA1 3 0UTR nts 292–300
could be a functional regulatory element, although the func-
tion of this element and its associated trans-factors is yet to
be investigated in vivo. Whilst there are multiple examples of
SNPs in 3 0UTRs, including BRCA1, being associated with dis-
ease (e.g. [49,50]), to our knowledge there are no reported
polymorphisms in the AU-rich region analysed in this study.
Of note, there are at least 11 SNPs in other regions of the
BRCA1 30UTR (dbSNP – http://www.ncbi.nlm.nih.gov/SNP/),
the functional signiﬁcance of which is yet to be determined.
Given the emerging role of 3 0UTRs as targets of microRNAs
(reviewed in [11]), it will be of considerable interest to deter-
mine whether such SNPs could aﬀect the activity of this new
class of regulators.
This manuscript provides the ﬁrst evidence that the BRCA1
3 0UTR may be important in controlling BRCA1 expression.
These initial ﬁndings call for a comprehensive investigation
into post-transcriptional regulation of BRCA1, including iden-
tiﬁcation of additional cis-acting regulatory elements, RNA-
binding proteins and also non-coding regulatory RNAs in-
volved.
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